| |
Unlocking the power of pharmacovigilance - An adaptive approach to an evolving drug safety environment
This document presents different approaches to the security issue in drug turnover.
|
| |
| |
Central and Eastern Europe - Prescription for growth
Part 4. With stable economies and solid medical credentials, the new Central and Eastern European members of the European Union look promising places for development and manufacturing.
Tylko angielska wersja językowa, 
(299 kB)
|
| |
| |
The Russian Federation - Prescription for growth
Part 5. From one side: six consecutive years of economic growth and a rise in living standards. On the other hand: the state-run healthcare system is seriously under-funded and most Russians cannot afford the best new drugs.
Tylko angielska wersja językowa,
(376 kB)
|
| |
| |
Corporate Finance Insights: Pharmaceutical Sector 2005/2006
Insights - an annual review of M&A activity and key trends within the pharmaceutical and healthcare sector.
Tylko angielska wersja językowa,
(402 kB)
|
| |
| |
Clinical trials in Poland
The aim of the report is to shed some light on the issues associated with conducting clinical trials, to determine the position of Poland in the European clinical trials market, to diagnose the key barriers to the development of that industry in Poland, and also to indicate the mechanisms which could be used to eliminate the existing obstacles.
178 kB |
| |
| |
IFRS: Issues and Solutions for the Pharmaceutical Industry, Part 2
Volume One of IFRS Issues and Solutions for the Pharmaceutical Industry generated significant discussion and debate. With pharmaceutical companies applying IFRS for the first time or applying the changes to IFRS in 2005, further questions have emerged.
|
| |
| |
A Better shape for the future:
Building value through integration and Partnerships
The new Pharmaceutical market survey from PricewaterhouseCoopers & Siemens.
European pharmaceutical market survey demonstrates demand for truly integrated multi-disciplinary services.
1390 kB |
| |
| |
Pharmaceutical Sector Insights: 2004-2005
Welcome to our seventh survey of global M&A in the pharmaceutical and related healthcare sectors from PricewaterhouseCoopers Corporate Finance. In this edition we review deal activity during 2004 and the outlook for 2005.
190 kB |
| |
| |
The IT antidote
NGP Magazine has just published an article written by Neil Davey with commentary extracts from Michael Mentesana and Michael Ferrante, directors in PricewaterhouseCoopers' US Pharmaceutical Advisory Services Group.
|
| |
| |
India - Prescription for growth*
Part 3: India 's booming middle class, manufacturing clout and nascent research base could prove a very tempting prospect for Western pharmaceutical firms.
|
| |
| |
Pharmaceutical Executive Magazine - April 2005
"Risky Business"
Pharmaceutical Executive magazine has just published an article authored by PricewaterhouseCoopers and the law firm King and Spalding on the compliance requirements involved in the government's drug price reporting programs.
|
| |
| |
Pharmaceutical Business Strategy - Mar/Apr 2005: Pharma Confronts Sarbanes-Oxley Compliance
Pharmaceutical Business Strategy has just published an extensive article examining the implementation issues related to Sarbanes-Oxley Section 404
With the deadlines for companies to attest to the quality of their internal controls fast approaching, PricewaterhouseCoopers Audit Partner Gerry Flynn joins other Big Four accounting firm partners in answering the question, "Is the industry ready?".
|
| |
| |
Latin America - Prescription for growth
Part 2: Despite poverty and political unrest, Latin America is fast becoming a much more attractive region in which to perform clinical trials and manufacturing.
|
| |
| |
Personalized medicine: the emerging pharmacogemics revolution
Each revolutionary change in human medicine, from antibiotics to painkillers to vaccines, has moved the practice of healthcare toward improved patient treatment. Pharmacogenomics, the next fundamental development in this area, promises to usher in an era of individualized patient care or personalized medicine.
|
| |
| |
IFRS: Issues and solutions for the pharmaceutical industry
Many publications have discussed the broader implications of IFRS but this is the first one that addressed the particular issues the pharmaceutical sector faces.
|
| |
| |
China - prescription for growth
Part 1: Most big drug makers already trade in China, but succeeding in what will soon be one of the world's largest markets is very difficult.
|
| |
| |
Pharmaceutical Industry Alert - January 2005
The 2004 Global Information Security Survey
This Pharmaceutical Alert outlines the results of a joint PwC, CIO Magazine and CSO Magazine survey of corporate IT and information security officers from 62 countries. Conducted on-line in 2004, the survey includes responses from 112 pharmaceutical industry executives from around the world.
|
| |
| |
Healing pharma's image
Neil Davey speaks to Anthony Farino, PricewaterhouseCoopers' US Pharmaceutical Advisory Services Leader, and Jeff Trewhitt, spokesman for the Pharmaceutical Research and Manufacturers of America about the current state of trust in the pharmaceutical industry and what the industry should do to address this growing problem.
3660 kB |
| |
